O
ADVM

OrbiMed’s Adverum Biotechnologies ADVM Stock Holding History

OrbiMed’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-550,114
Closed -$54.2M – 160
2021
Q1 		$54.2M Hold
550,114
– – 0.51% 55
2020
Q4 		$59.6M Buy
550,114
+91,680
+20% +$11.3M 0.52% 54
2020
Q3 		$47.2M Buy
458,434
+129,360
+39% +$19.4M 0.59% 54
2020
Q2 		$68.7M Sell
329,074
-15,990
-5% -$2.83M 0.97% 31
2020
Q1 		$33.7M Sell
345,064
-89,155
-21% -$10.4M 0.57% 47
2019
Q4 		$50M Buy
434,219
+32,922
+8% +$2.9M 0.71% 45
2019
Q3 		$21.9M Buy
401,297
+205,277
+105% +$23.1M 0.42% 57
2019
Q2 		$23.3M Buy
196,020
+71,700
+58% +$5.93M 0.36% 62
2019
Q1 		$6.51M Buy
+124,320
New +$5.03M 0.1% 100
2015
Q2 		– Sell
-28,390
Closed -$9.58M – 138
2015
Q1 		$11.5M Buy
+28,390
New +$12M 0.1% 98

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed's ADVM Position: Q2 2021 in Review

OrbiMed sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 550,114 shares — an estimated $54.2M sold.

OrbiMed first reported a position in ADVM in Q1 2015 and held it in 10 quarters. The position peaked at $68.7M in Q2 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • OrbiMed reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • OrbiMed sold 550,114 Adverum Biotechnologies shares in Q2 2021, an estimated $54.2M.
  • OrbiMed first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 10 quarters.
  • OrbiMed's Adverum Biotechnologies position peaked at $68.7M in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.